礼来新型降脂药数据公布,可将心脏病遗传风险因素降低94%

第一财经
31 Mar

当地时间3月30日,礼来公司在美国心脏病学会会议上公布了在研降脂药lepodisiran的一项临床数据,显示该药物最高剂量在中期试验中将心脏病遗传风险因素的水平降低94%。lepodisiran是一种靶向脂蛋白 (a) (也称:Lp(a))的药物,脂蛋白(a)是心脏病的遗传风险因素,目前全球范围内都没有此类药物获批。据该药物的研究负责人、克利夫兰诊所心脏病专家Steven Nissen介绍,该药物...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10